Journal of Clinical Microbiology, April 2002, p. 1174-1180, Vol. 40, No. 4
0095-1137/02/$04.00+0 DOI: 10.1128/JCM.40.4.1174-1180.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Recombinant BBK32 Protein in Serodiagnosis of Early and Late Lyme Borreliosis
Tero Heikkilä,1,2 Ilkka Seppälä,2,3 Harri Saxén,1 Jaana Panelius,2 Miikka Peltomaa,4 Tiina Julin,5 Sten-Anders Carlsson,5 and Pekka Lahdenne1*
Hospital for Children and Adolescents,1
Department of Otorhinolaryngology, University of Helsinki,4
Laboratory Diagnostics, Helsinki University Central Hospital, FIN-00290 Helsinki,3
Department of Bacteriology and Immunology, Haartman Institute, FIN-00014 Helsinki,2
Åland Central Hospital, 22100 Mariehamn, Finland5
Received 24 August 2001/
Returned for modification 29 November 2001/
Accepted 30 December 2001
Borrelial protein BBK32 was evaluated as an antigen in the serodiagnosis of early and disseminated Lyme borreliosis (LB). bbk32 was cloned and sequenced from eight isolates of the three pathogenic Borrelia species. The identities between the amino acid sequences of the BBK32 proteins from Borrelia burgdorferi sensu stricto, B. garinii, and B. afzelii isolates were 71 to 100%. By immunoglobulin G (IgG) Western blotting (WB) or enzyme-linked immunosorbent assay (ELISA), up to 74 and 100% of acute- and convalescent-phase samples, respectively, from 23 patients with erythema migrans (EM) were positive for recombinant BBK32 protein from B. afzelii. In the serology of disseminated LB, the three variant BBK32 antigens cross-reacted. In total, 14 of 14 samples from patients with neuroborreliosis and 15 of 15 samples from patients with Lyme arthritis were positive. The specificities of the IgG ELISA with the variant BBK32 antigens for EM and disseminated borreliosis were 81 to 92% and 89 to 95%, respectively. Our findings indicate that the BBK32 proteins are promising serodiagnostic antigens for the detection of early and disseminated LB but that variant BBK32 proteins may be needed either in parallel or in combination with an immunoassay for LB to cover all the relevant borrelial species that cause the disease.
* Corresponding author. Mailing address: Hospital for Children and Adolescents, University of Helsinki, Stenbäckinkatu 11, FIN-00290 Helsinki, Finland. Phone: 358-9-4717 2762. Fax: 358-9-4717 6712. E-mail: pekka.lahdenne{at}hus.fi.
Journal of Clinical Microbiology, April 2002, p. 1174-1180, Vol. 40, No. 4
0095-1137/02/$04.00+0 DOI: 10.1128/JCM.40.4.1174-1180.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Nardelli, D. T., Callister, S. M., Schell, R. F.
(2008). Lyme Arthritis: Current Concepts and a Change in Paradigm. CVI
15: 21-34
[Full Text]
-
Lahdenne, P., Sarvas, H., Kajanus, R., Eholuoto, M., Sillanpaa, H., Seppala, I.
(2006). Antigenicity of borrelial protein BBK32 fragments in early Lyme borreliosis.. J Med Microbiol
55: 1499-1504
[Abstract]
[Full Text]
-
Mueller, M., Bunk, S., Diterich, I., Weichel, M., Rauter, C., Hassler, D., Hermann, C., Crameri, R., Hartung, T.
(2006). Identification of Borrelia burgdorferi Ribosomal Protein L25 by the Phage Surface Display Method and Evaluation of the Protein's Value for Serodiagnosis.. J. Clin. Microbiol.
44: 3778-3780
[Abstract]
[Full Text]
-
Li, X., Liu, X., Beck, D. S., Kantor, F. S., Fikrig, E.
(2006). Borrelia burgdorferi Lacking BBK32, a Fibronectin-Binding Protein, Retains Full Pathogenicity.. Infect. Immun.
74: 3305-3313
[Abstract]
[Full Text]
-
Aguero-Rosenfeld, M. E., Wang, G., Schwartz, I., Wormser, G. P.
(2005). Diagnosis of Lyme Borreliosis. Clin. Microbiol. Rev.
18: 484-509
[Abstract]
[Full Text]
-
Lahdenne, P., Panelius, J., Saxen, H., Heikkila, T., Sillanpaa, H., Peltomaa, M., Arnez, M., Huppertz, H.-I., Seppala, I. J.T.
(2003). Improved serodiagnosis of erythema migrans using novel recombinant borrelial BBK32 antigens. J Med Microbiol
52: 563-567
[Abstract]
[Full Text]
Copyright © 2002 by the American Society for Microbiology. All rights reserved.